CD4-specific CAR is a chimeric antigen receptor immunotherapy treatment designed to treat lymphoma/leukemia expressing CD4 antigen. CD4+ T cell lymphomas are a subset of leukemias and lymphomas that are positive for the surface protein CD4. The purpose of this study is to evaluate the efficacy and safety of CD4 CAR T cells.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent; Patients volunteer to participate in the research
Diagnosis is mainly based on the World Health Organization (WHO) 2008
Patients have exhausted standard therapeutic options
Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks
Female must be not pregnant during the study
You may not be if
Patients declining to consent for treatment
Prior solid organ transplantation
Potentially curative therapy including chemotherapy or hematopoietic cell transplant
Any drug used for GVHD must be stopped \>1 week
Clareo Health | CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies
